PLANTATION, Fla., Sept. 10, 2013 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP), a Nevada corporation (the "Company"), announced that effective today the trading symbol for its common stock has changed from "BLFLD" to "NTRP," reflecting the Company's name change from BlueFlash Communications, Inc., to Neurotrope Inc., in connection with its reverse merger with Neurotrope BioScience, Inc., which was completed on August 23, 2013, as previously announced. Shares of the Company's common stock are quoted in the OTCQB marketplace.
About Neurotrope Inc.
The Company's wholly owned subsidiary, Neurotrope BioScience, Inc. ("Neurotrope BioScience"), was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope BioScience was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a g
|SOURCE Neurotrope, Inc.|
Copyright©2012 PR Newswire.
All rights reserved